Gyre Therapeutics, Inc. expected to post a loss of 13 cents a share - Earnings Preview

Gyre Therapeutics

07/08/2026 16:01

Gyre Therapeutics, Inc. GYRE.OQ GYRE.O is expected to  show a fall in quarterly revenue when it reports  results on August 7 for the period ending September 30 2026
The San Diego California-based  company is expected to report a 13.4% decrease in revenue to $26.47 million from $30.56 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.
​LSEG's mean analyst estimate for Gyre Therapeutics, Inc. is for a loss of 13 cents per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Gyre Therapeutics, Inc. is $18.00, about 181.2% above its last closing price of $6.40
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Jun. 30 2026
-0.09
-0.12
Missed
-33.3
Mar. 31 2026
-0.07
-0.07
-0.04
Beat
38.6
Dec. 31 2025
0.01
0.06
0.05
Missed
-11.8​
Sep. 30 2025
0.02
0.03
0.08
Beat
200
​​Jun. 30 2025
0.03
0.03
0.02
Missed
-33.3
Mar. 31 2025
0.03
0.03
0.03
Met
0​
Dec. 31 2024
0.04
0.04
0.00
Missed
-102.9
This summary was machine generated August 7 at 15:01 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)